BRCA1 intronic Alu elements drive gene rearrangements and PARP inhibitor resistance

BRCA1 mutant carcinomas are sensitive to PARP inhibitor (PARPi) therapy; however, resistance arises. BRCA1 BRCT domain mutant proteins do not fold correctly and are subject to proteasomal degradation, resulting in PARPi sensitivity. In this study, we show that cell lines and patient-derived tumors,...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Nat Commun
Main Authors: Wang, Yifan, Bernhardy, Andrea J., Nacson, Joseph, Krais, John J., Tan, Yin-Fei, Nicolas, Emmanuelle, Radke, Marc R., Handorf, Elizabeth, Llop-Guevara, Alba, Balmaña, Judith, Swisher, Elizabeth M., Serra, Violeta, Peri, Suraj, Johnson, Neil
Formato: Artigo
Idioma:Inglês
Publicado: Nature Publishing Group UK 2019
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC6906494/
https://ncbi.nlm.nih.gov/pubmed/31827092
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41467-019-13530-6
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares